Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-EN Version v2-EN
Language English English
Date Updated 2025-10-01 2025-09-30
Drug Identification Number 02248302 02248302
Brand name MULTIHANCE MULTIHANCE
Common or Proper name MultiHance (Gadobenate Dimeglumine) MultiHance (Gadobenate Dimeglumine)
Company Name BRACCO IMAGING CANADA BRACCO IMAGING CANADA
Ingredients GADOBENATE DIMEGLUMINE GADOBENATE DIMEGLUMINE
Strength(s) 529MG 529MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size Box of 5 vials of 5ml Box of 5 vials of 5ml
ATC code V08CA V08CA
ATC description MAGNETIC RESONANCE IMAGING CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2025-09-30 2025-09-30
Actual start date 2025-09-30 2025-09-30
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments We are experiencing a supply shortage for MultiHance 5 x 5 ml (gadobenate dimeglumine injection, 529 mg/ml) – SKU 516421/Internal Code 700831. Given the low demand for this format, an analysis is underway within the organization to assess the relevance of continuing to commercialize this format. We are experiencing a supply shortage for MultiHance 5 x 5 ml (gadobenate dimeglumine injection, 529 mg/ml) – SKU 516421/Internal Code 700831. Given the low demand for this format, an analysis is underway within the organization to assess the relevance of continuing to commercialize this format.
Health Canada comments